MBX-SD-201

MBX-SD-201 is an investigational whole microbiome therapeutic developed by MyBiotics for the treatment of *Clostridium difficile* infection (CDI). It is designed as an oral, feces-free alternative to traditional fecal microbiota transplantation (FMT), utilizing a proprietary technology that enables the industrial-scale production of a powder closely resembling a selected human microbiome sample. This approach aims to restore and maintain healthy gut flora, providing long-term recovery and potentially replacing FMT in clinical practice. The product leverages MyBiotics' MyCrobe technology, which enhances bacterial colonization and survival in the human body. As of early 2021, MBX-SD-201 was in preclinical development for CDI[1][2][3][4][5].